(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
Blueprint Medicines Corporation
Blueprint Medicines Corporation
Blueprint Medicines Corporation
MacroGenics
Cogent Biosciences, Inc.
Telios Pharma, Inc.